BXCL502

BXCL502 is a sublingual film formulation of the atypical antipsychotic **olanzapine**, developed by **BioXcel Therapeutics** using its proprietary **EvolverAI** platform. It is designed for the acute treatment of **agitation** associated with neuropsychiatric conditions, particularly **dementia** (including Alzheimer's disease). By utilizing a sublingual film delivery system, BXCL502 aims to provide a rapid onset of action and ease of administration for patients who may be uncooperative or have difficulty swallowing, potentially offering a non-invasive alternative to intramuscular injections in emergency or clinical settings. The drug is part of BioXcel's broader agitation franchise, which also includes the FDA-approved dexmedetomidine film (BXCL501).

Other names

olanzapine sublingual film